Cohance Lifesciences Limited (NSE:COHANCE)
India
· Delayed Price · Currency is INR 282.55
+2.65 (0.95%)
At close: Mar 9, 2026
Cohance Lifesciences Revenue
Cohance Lifesciences had revenue of 5.45B INR in the quarter ending December 31, 2025, with 77.29% growth. This brings the company's revenue in the last twelve months to 10.79B, up 2.90% year-over-year. In the fiscal year ending March 31, 2025, Cohance Lifesciences had annual revenue of 11.98B with 13.91% growth.
Revenue (ttm)
10.79B
Revenue Growth
+2.90%
P/S Ratio
10.02
Revenue / Employee
8.90M
Employees
1,212
Market Cap
108.09B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Alivus Life Sciences | 25.12B |
| Alembic Pharmaceuticals | 72.67B |
| Strides Pharma Science | 47.26B |
| Akums Drugs and Pharmaceuticals | 42.60B |
| NATCO Pharma | 45.63B |
| Eris Lifesciences | 30.65B |
| Aarti Pharmalabs | 18.01B |
| Piramal Pharma | 88.71B |